These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

610 related articles for article (PubMed ID: 29627023)

  • 21. Cognitive dysfunction in Tunisian LRRK2 associated Parkinson's disease.
    Ben Sassi S; Nabli F; Hentati E; Nahdi H; Trabelsi M; Ben Ayed H; Amouri R; Duda JE; Farrer MJ; Hentati F
    Parkinsonism Relat Disord; 2012 Mar; 18(3):243-6. PubMed ID: 22056842
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Progression in the LRRK2-Asssociated Parkinson Disease Population.
    Saunders-Pullman R; Mirelman A; Alcalay RN; Wang C; Ortega RA; Raymond D; Mejia-Santana H; Orbe-Reilly M; Johannes BA; Thaler A; Ozelius L; Orr-Urtreger A; Marder KS; Giladi N; Bressman SB;
    JAMA Neurol; 2018 Mar; 75(3):312-319. PubMed ID: 29309488
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The LRRK2 G2019S mutation status does not affect the outcome of subthalamic stimulation in patients with Parkinson's disease.
    Greenbaum L; Israeli-Korn SD; Cohen OS; Elincx-Benizri S; Yahalom G; Kozlova E; Strauss H; Molshatzki N; Inzelberg R; Spiegelmann R; Israel Z; Hassin-Baer S
    Parkinsonism Relat Disord; 2013 Nov; 19(11):1053-6. PubMed ID: 23932063
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Association of Dual LRRK2 G2019S and GBA Variations With Parkinson Disease Progression.
    Ortega RA; Wang C; Raymond D; Bryant N; Scherzer CR; Thaler A; Alcalay RN; West AB; Mirelman A; Kuras Y; Marder KS; Giladi N; Ozelius LJ; Bressman SB; Saunders-Pullman R
    JAMA Netw Open; 2021 Apr; 4(4):e215845. PubMed ID: 33881531
    [TBL] [Abstract][Full Text] [Related]  

  • 25. CSF Nrf2 and HSPA8 in Parkinson's disease patients with and without LRRK2 gene mutations.
    Loeffler DA; Smith LM; Coffey MP; Aasly JO; LeWitt PA
    J Neural Transm (Vienna); 2016 Mar; 123(3):179-87. PubMed ID: 26526034
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Increased peripheral inflammation in asymptomatic leucine-rich repeat kinase 2 mutation carriers.
    Dzamko N; Rowe DB; Halliday GM
    Mov Disord; 2016 Jun; 31(6):889-97. PubMed ID: 26917005
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Higher Urine bis(Monoacylglycerol)Phosphate Levels in LRRK2 G2019S Mutation Carriers: Implications for Therapeutic Development.
    Alcalay RN; Hsieh F; Tengstrand E; Padmanabhan S; Baptista M; Kehoe C; Narayan S; Boehme AK; Merchant K
    Mov Disord; 2020 Jan; 35(1):134-141. PubMed ID: 31505072
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The Effect of p.G2019S Mutation in the
    Usenko TS; Timofeeva A; Beletskaia M; Basharova K; Baydakova G; Bezrukova A; Grunina M; Emelyanov A; Miliukhina I; Zakharova E; Pchelina S
    J Integr Neurosci; 2024 Jan; 23(1):16. PubMed ID: 38287861
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Nonmotor symptoms in healthy Ashkenazi Jewish carriers of the G2019S mutation in the LRRK2 gene.
    Mirelman A; Alcalay RN; Saunders-Pullman R; Yasinovsky K; Thaler A; Gurevich T; Mejia-Santana H; Raymond D; Gana-Weisz M; Bar-Shira A; Ozelius L; Clark L; Orr-Urtreger A; Bressman S; Marder K; Giladi N;
    Mov Disord; 2015 Jun; 30(7):981-6. PubMed ID: 25809001
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A Disease Progression Model to Quantify the Nonmotor Symptoms of Parkinson's Disease in Participants With Leucine-Rich Repeat Kinase 2 Mutation.
    Ahamadi M; Mehrotra N; Hanan N; Lai Yee K; Gheyas F; Anton J; Bani M; Boroojerdi B; Smit H; Weidemann J; Macha S; Thuillier V; Chen C; Yang M; Williams-Gray CH; Stebbins GT; Pagano G; Hang Y; Marek K; Venuto CS; Javidnia M; Dexter D; Pedata A; Stafford B; Akalu M; Stephenson D; Romero K; Sinha V;
    Clin Pharmacol Ther; 2021 Aug; 110(2):508-518. PubMed ID: 33894056
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Age-specific penetrance of LRRK2 G2019S in the Michael J. Fox Ashkenazi Jewish LRRK2 Consortium.
    Marder K; Wang Y; Alcalay RN; Mejia-Santana H; Tang MX; Lee A; Raymond D; Mirelman A; Saunders-Pullman R; Clark L; Ozelius L; Orr-Urtreger A; Giladi N; Bressman S;
    Neurology; 2015 Jul; 85(1):89-95. PubMed ID: 26062626
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Low-variance RNAs identify Parkinson's disease molecular signature in blood.
    Chikina MD; Gerald CP; Li X; Ge Y; Pincas H; Nair VD; Wong AK; Krishnan A; Troyanskaya OG; Raymond D; Saunders-Pullman R; Bressman SB; Yue Z; Sealfon SC
    Mov Disord; 2015 May; 30(6):813-21. PubMed ID: 25786808
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cognitive and behavioral symptoms in Parkinson's disease patients with the G2019S and R1441G mutations of the LRRK2 gene.
    Somme JH; Molano Salazar A; Gonzalez A; Tijero B; Berganzo K; Lezcano E; Fernandez Martinez M; Zarranz JJ; Gómez-Esteban JC
    Parkinsonism Relat Disord; 2015 May; 21(5):494-9. PubMed ID: 25840672
    [TBL] [Abstract][Full Text] [Related]  

  • 34. G2019S mutation of the leucine-rich repeat kinase 2 gene in a cohort of Egyptian patients with Parkinson's disease.
    Hashad DI; Abou-Zeid AA; Achmawy GA; Allah HM; Saad MA
    Genet Test Mol Biomarkers; 2011 Dec; 15(12):861-6. PubMed ID: 21699405
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Glucocerebrosidase activity in Parkinson's disease with and without GBA mutations.
    Alcalay RN; Levy OA; Waters CC; Fahn S; Ford B; Kuo SH; Mazzoni P; Pauciulo MW; Nichols WC; Gan-Or Z; Rouleau GA; Chung WK; Wolf P; Oliva P; Keutzer J; Marder K; Zhang X
    Brain; 2015 Sep; 138(Pt 9):2648-58. PubMed ID: 26117366
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The LRRK2 G2019S mutation is associated with Parkinson disease and concomitant non-skin cancers.
    Inzelberg R; Cohen OS; Aharon-Peretz J; Schlesinger I; Gershoni-Baruch R; Djaldetti R; Nitsan Z; Ephraty L; Tunkel O; Kozlova E; Inzelberg L; Kaplan N; Fixler Mehr T; Mory A; Dagan E; Schechtman E; Friedman E; Hassin-Baer S
    Neurology; 2012 Mar; 78(11):781-6. PubMed ID: 22323743
    [TBL] [Abstract][Full Text] [Related]  

  • 37. LRRK2 mutations in Parkinson's disease: confirmation of a gender effect in the Italian population.
    Cilia R; Siri C; Rusconi D; Allegra R; Ghiglietti A; Sacilotto G; Zini M; Zecchinelli AL; Asselta R; Duga S; Paganoni AM; Pezzoli G; Seia M; Goldwurm S
    Parkinsonism Relat Disord; 2014 Aug; 20(8):911-4. PubMed ID: 24816003
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Serotonin and dopamine transporter PET changes in the premotor phase of LRRK2 parkinsonism: cross-sectional studies.
    Wile DJ; Agarwal PA; Schulzer M; Mak E; Dinelle K; Shahinfard E; Vafai N; Hasegawa K; Zhang J; McKenzie J; Neilson N; Strongosky A; Uitti RJ; Guttman M; Zabetian CP; Ding YS; Adam M; Aasly J; Wszolek ZK; Farrer M; Sossi V; Stoessl AJ
    Lancet Neurol; 2017 May; 16(5):351-359. PubMed ID: 28336296
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comprehensive analysis of clinical and biological features in Parkinson's disease associated with the LRRK2 G2019S mutation: Data from the PPMI study.
    Sun X; Dou K; Xue L; Xie Y; Yang Y; Xie A
    Clin Transl Sci; 2024 Jan; 17(1):e13720. PubMed ID: 38266062
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A common leucine-rich repeat kinase 2 gene mutation in familial and sporadic Parkinson's disease in Russia.
    Illarioshkin SN; Shadrina MI; Slominsky PA; Bespalova EV; Zagorovskaya TB; Bagyeva GKh; Markova ED; Limborska SA; Ivanova-Smolenskaya IA
    Eur J Neurol; 2007 Apr; 14(4):413-7. PubMed ID: 17388990
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 31.